Olema Oncology To Participate In Morgan Stanley 22Nd Annual Global Healthcare Conference

2024-08-21 08:34:00

(MENAFN- GlobeNewsWire - Nasdaq) SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”,“Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that its management team will participate in the following upcoming investor conference:

Morgan Stanley 22nd Annual Global Healthcare Conference
Date: Wednesday, September 4, 2024, at 7:45 a.m. ET
Location: Marriott Marquis in New York, NY
Format: Fireside Chat

A live webcast of the Fireside Chat will be available under the News & Events section of Olema's investor relations website at ir.olema.com . The webcasts will be archived for at least 30 days.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at .

Contact:
Geoffrey Mogilner, Investor Relations and Communications
...

MENAFN21082024004107003653ID1108584768

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.